CHARACTERIZATION OF THE DOLUTEGRAVIR MONOTHERAPY-ACQUIRED S230R RESISTANCE MUTATION
Dolutegravir (DTG) is a potent and well tolerated integrase strand-transfer inhibitor (INSTI) with a high barrier to resistance, which makes it a suitable candidate for antiretroviral maintenance monotherapy and simplified regimens. Here, we report the emergence of a S230R substitution in two patients who experienced virological failure after switching to DTG monotherapy from triple therapy…